Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer
Metrics: PDF 557 views | Full Text 1071 views | ?
C. Andrew Boswell1, Daniela Bumbaca Yadav1, Eduardo E. Mundo1,2, Shang-Fan Yu1, Jennifer Arca Lacap1, Aimee Fourie-O’Donohue1, Katherine R. Kozak1, Gregory Z. Ferl1, Crystal Zhang1, Jason Ho1, Sheila Ulufatu1, Leslie A. Khawli1,3 and Kedan Lin1,4
1 Genentech Research and Early Development, South San Francisco, 94080 CA, USA
2 Present address: Department of Safety Assessment, Nektar Therapeutics, San Francisco, 94158 CA, USA
3 Present address: Department of Pathology and Laboratory Medicine, Keck School of Medicine of USC, Los Angeles, 90033 CA, USA
4 Present address: Clinical Development and US Operation, Innovent Biologics, South San Francisco, 94080 CA, USA
|C. Andrew Boswell,||email:||firstname.lastname@example.org|
Keywords: antibody-drug conjugate; prostate cancer; pharmacokinetics; TENB2; imaging
Received: August 01, 2019 Accepted: October 01, 2019 Published: October 22, 2019
TENB2, a transmembrane proteoglycan protein, is a promising target for antibody drug conjugate (ADC) therapy due to overexpression in human prostate tumors and rapid internalization. We previously characterized how predosing with parental anti-TENB2 monoclonal antibody (mAb) at 1 mg/kg in a patient-derived LuCap77 explant model with high (3+) TENB2 expression could (i) block target-mediated intestinal uptake of tracer (< 0.1 mg/kg) levels of radiolabeled anti-TENB2-monomethyl auristatin E ADC while preserving tumor uptake, and (ii) maintain efficacy relative to ADC alone. Here, we systematically revisit this strategy to evaluate the effects of predosing on tumor uptake and efficacy in LuCap96.1, a low TENB2-expressing (1+) patient-derived model that is more responsive to ADC therapy than LuCap77. Importantly, rather than using tracer (< 0.1 mg/kg) levels, radiolabeled ADC tumor uptake was assessed at 1 mg/kg – one of the doses evaluated in the tumor growth inhibition study – in an effort to bridge tissue distribution (PK) with efficacy (PD). Predosing with mAb up to 1 mg/kg had no effect on efficacy. These findings warrant further investigations to determine whether predosing prior to ADC therapy might improve therapeutic index by preventing ADC disposition and possible toxicological liabilities in antigen-expressing healthy tissues.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.